Shanghai Medicilon Inc.

  On the way to fight against tumors, we may encounter many "enemies", and most of the time it is difficult to get through.  However, when faced with the formidable enemy of brain metastasis, they often lose.  Relevant data show that about 25%-40% of malignant tumors will develop brain metastasis during the course of the disease. Even with targeted therapy drugs, many will fail before they reach the metastasis. Why is brain metastasis so common and dangerous?  We have to mention the blood-brain barrier that blocks drugs from entering the brain. How to allow drugs to break through the blood-brain barrier is a major and important problem in the treatment of tumor brain metastasis.  Fortunately, there are always scientists who are not afraid of war and are bound to attack the blood-brain barrier and lead drugs across the blood-brain barrier. One of the examples is Dr. Chen Chen that we interviewed today.  As a scientist with more than 20 years of experience in...

  Shanghai, China/San Diego,USA - August 2, 2023, ABM Therapeutics announced that its self-developed small molecule BRAF inhibitor ABM-1310 has obtained orphan drug qualification from the US FDA for the treatment of BRAF V600 mutant brain glioblastoma (GBM). In the research and development of ABM-1310, the  chemical FTE (Full-time equivalent)  team of Shanghai Medicilon Inc provided  drug discovery services  in a flexible cooperation mode.  It has laid a solid foundation for ABM Therapeutics' ABM-1310 to obtain the US FDA Orphan Drug Qualification. Medicilon Chemical FTE Team Facilitate Rapid Discovery of Innovative Drugs The chemical FTE team of Medicilon can serve clients in different stages of drug development, including the generation and optimization of hit compounds, the identification and optimization of lead compounds, synthesis amplification chemical process research and other services.  This collaboration model is based on client and project ...